Results 201 to 210 of about 48,636 (310)

The Current Landscape of Modular CAR T Cells. [PDF]

Int J Mol Sci
Joechner AH, Mach M, Li Z.
europepmc   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. [PDF]

Blood Cancer Discov
Lüönd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, Choi SM, Ruella M, Fraietta JA, Schuster SJ, Brogdon JL, Niederst MJ, Treanor LM.   +12 more
europepmc   +1 more source

Lymphocyte Subtypes in Local Inflammatory Response: A Comparative Analysis of Simple and Complicated Appendicitis. [PDF]

Medicina (Kaunas)
Zecevic M, Zivanovic D, Zivkovic N, Velickov A, Marjanovic V, Marjanovic Z, Milenkovic S, Sretenovic A.   +7 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Daratumumab for Treatment of Refractory Podocytopathy: A Case Report. [PDF]

Kidney Med
Curto A, Martinez Leon VJ, Geara AS.
europepmc   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, Volume 13, Issue 14, 9 March 2026.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics. [PDF]

Oncoimmunology
Xue E, Deng X, Doffe F, Kroemer G, Kepp O.   +4 more
europepmc   +1 more source

Population and single‐cell analyses reveal immune cell‐specific expression profiles associated with Alzheimer's disease risk

Alzheimer's &Dementia, Volume 22, Issue 3, -Not available-.
Abstract INTRODUCTION Dysregulation of the peripheral immune system may increase Alzheimer's disease (AD) risk, but the underlying cell type‐specific mechanisms remain unclear. METHODS We conducted Mendelian randomization and colocalization analyses of 4489 genes using single‐cell expression quantitative trait locus data from unstimulated and ...
Joni V. Lindbohm, Martin Stražar, Hang‐Mao Lee, Orr Ashenberg, Nina Mars, Pyry N. Sipilä, Samuli Ripatti, Dan Graham, Mika Kivimäki, Ramnik J. Xavier   +9 more
wiley   +1 more source

Special Issue: Antibody Therapy for Hematologic Malignancies. [PDF]

Int J Mol Sci
Butchar JP.
europepmc   +1 more source